Windler E
Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Hamburg.
Z Arztl Fortbild (Jena). 1996 Feb;90(1):7-10.
The Scandinavian Simvastatin Survival Study (4S-Studie) has provided proof beyond any doubt that reduction of plasma cholesterol decreases mortality. The enormous rise of morbidity and mortality from cardiovascular disease in both gender calls for preventative measures as an urgent task. With a reduction of cardiac events by 30-40% and of mortality in the same order of magnitude, cholesterol lowering and increase in HDL-cholesterol are most effective measures for the treatment of coronary artery disease. However, not treatment of late stages of the disease, but primary prevention to reduce the incidence of coronary artery disease in this country should be the principle aim. Thus, the international guidelines for the treatment of lipid disorders considering the individual patient's risk profile have been revised.
斯堪的纳维亚辛伐他汀生存研究(4S研究)已毫无疑问地证明,降低血浆胆固醇可降低死亡率。两性中心血管疾病发病率和死亡率的大幅上升,使得采取预防措施成为一项紧迫任务。降低胆固醇以及提高高密度脂蛋白胆固醇水平,可使心脏事件减少30%-40%,死亡率也有同等程度的降低,这是治疗冠状动脉疾病最有效的措施。然而,治疗该病的晚期并非首要目标,首要目标应是在本国进行一级预防以降低冠状动脉疾病的发病率。因此,考虑到个体患者风险状况的国际血脂异常治疗指南已得到修订。